EXG-5003 is an intradermally-injected, temperature-controllable, self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.
EXG-5003 is designed to induce robust cellular immunity to provide broad protection across variants. Elixirgen Therapeutics is currently dosing volunteers with EXG-5003 in a Phase 1/2 Clinical Trial in Japan that started in May 2021.
Additional terms of the agreement were not disclosed.
Elixirgen Therapeutics, Inc. is a clinical stage biotechnology company which is focused on cell and gene therapy and vaccine development.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval